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This thesis is dedicated  
To persons affected by psychotic disorders past and present, 
To health care practitioners, especially those concerned with psychiatric illnesses and 
cardiovascular diseases, 
To exercise physiologists, physiotherapists and physical trainers. 
  
  
ABSTRACT 
Psychotic disorders such as schizophrenia maintain a 1% point prevalence in society at large. 
They cause much suffering to the patients and exact grave costs on society. There is an urgent 
need for better diagnosis and treatment of psychotic disorders. Patients with psychotic disorders 
are primarily treated for deteriorating psychiatric symptoms and often somatic comorbidities 
are overlooked. Accelerated ageing and metabolic comorbidities such as adiposity, diabetes 
and cardiovascular disease are common in psychosis patients, with often 15-20 years shortened 
life expectancy. The main pathophysiological elements of psychotic disorders and 
schizophrenia remain elusive. There is increasing evidence to suggest that psychotic disorders 
such as schizophrenia are in fact a group of related disorders advocating a more individualized 
evidence-based treatment than that currently available. Biomarkers are by definition useful 
tools for describing individual patient centered disease states or selecting treatment approaches. 
The main aim of this thesis was to investigate putative blood biomarkers which describe the 
previously reported ongoing pathological processes inflammation, mitochondrial dysfunction 
and metabolic disturbances.  In paper I we assessed, mitochondrial DNA (mtDNA), a proxy 
for mitochondrial dysfunction in patients of psychotic disorder. We additionally investigated 
the effect of anti-psychotic drug treatment on the mtDNA copy number of neuro-epithelial stem 
cell derived human neurons.  In paper II and III, we explored plasma levels of GDF-15, an 
anti-inflammation marker gaining traction in the field of cardiovascular disease, in the context 
of psychotic disorders. In paper IV we report the initial findings of a larger study of 
inflammation in first episode psychosis (FEP) patients recruited for exercise intervention. We 
investigated a pre-selected group of cytokines, ligands and receptors in patients with FEP. 
The major findings from this thesis work includes 1) We were the first to report elevated plasma 
GDF-15 levels in patients with psychotic disorders compared to healthy age and gender 
matched controls. 2) We detected that GDF-15 robustly associated with aging and levels of 
established analyte biomarkers for cardiovascular disease, while not with the acute 
inflammation marker C-reactive protein. 3) Treatment with clozapine and risperidone was 
associated with a depletion of whole blood and neuronal mtDNA. 4) In those not treated with 
clozapine or risperidone, the mtDNA copy number was reduced with age and with more severe 
psychosis. 5) Most FEP patients, 70%, had markedly elevated plasma fractalkine levels, while 
the rest had low healthy control levels, reflecting an on/off pattern.  FEP patients could be 
divided into four immunologically distinct groups categorized by how fractalkine levels 
changed over 12 weeks physical exercise. One group likely represents patients with milder 
psychosis. The present thesis provides findings from pre-clinical and basic research with a 
potential to support the development of better clinical therapy for patients of psychotic 
disorders. 
Keywords: mitochondrial DNA, ageing, inflammation, psychosis, anti-psychotic drugs, 
schizophrenia, exercise, fractalkine, GDF-15 
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1 INTRODUCTION 
1.1 PSYCHOSIS AND SCHIZOPHRENIA 
1.1.1 Symptoms and Diagnosis 
Psychosis can be defined as a dissociation from reality based on irregular thoughts and 
impediment of cognitive function. Two examples of psychiatric diagnoses amongst many 
disorders which present psychotic symptoms are bipolar disorder Type I (BD I) and 
schizophrenia (SZ). To obtain a diagnosis of SZ, at least 2 main psychotic symptoms should 
be strongly prevalent in an individual over the course of a month and mental disturbances 
should be present over a period of 6 months. Based on the criteria of the American Psychiatric 
Association’s fourth revision of the Diagnostic and Statistical Manual of Mental Disorders 
[DSM-IV;1] or the World Health Organization’s 10th edition of the International Statistical 
Classification of Diseases and Related Health Problems [ICD-10;2] these psychotic symptoms 
include, hallucinations, delusional beliefs, catatonic behavior, negative affect and irregular 
speech. Generally, a trained psychiatrist considering the cultural norms of the patient makes a 
diagnosis using the above-mentioned instruments, using her observations and account of 
responses to questionnaires over a period of time.  
1.1.2 Etiology of Schizophrenia a psychotic disorder 
SZ is a debilitating psychiatric disorder with a prevalence estimated at 1% of the world 
population 3. It is a syndrome that causes a range of detrimental symptoms to afflicted 
individuals such as loss of cognitive function, social and occupational functioning and 
increased risks of lifetime morbidity and mortality 4. The cause of SZ is far from certain and 
likely heterogeneous. However, strong links have been established to the genetic makeup of an 
individual, through twin concordance studies, in particular, showing that the polygenic model 
best explains empirical findings 5. A Finnish adoptive family study found that although there 
was evidence for a genetic hypothesis in SZ, biologically predisposed offspring in disturbed or 
stressful adoptive families were most vulnerable to the syndrome, thus illustrating the effect of 
the environment on disease etiology 6. The mechanism by which genetic traits combine with 
environmental effects to give rise to SZ is poorly understood however there is evidence that 
malnutrition before birth, exposure to certain virus prenatally, obstetric complications, heavy 
cannabinoid use and challenging socio-economic factors are some of the environmental factors 
that have been linked with SZ 7-11. Increasingly, regulatory elements of gene expression such 
as non-coding RNA 12 and epigenetic mechanisms 13 have been implicated in SZ etiology. The 
action of dopamine antagonists in ameliorating SZ positive symptoms and hypofunction of 
glutamatergic signaling via NMDA receptors implicated in both positive and negative 
symptoms of SZ has led to hypotheses that the dopaminergic and glutamatergic pathways, 
when disrupted lead to the constellation of symptoms described as SZ14,15. Complimentary to 
these twin pillars of SZ etiology, there is a developing theory that explains the neuropathology 
of SZ, through inflammation. Here the theory posits that genetic anomalies in the presence of 
environmental insults manifest as chronic inflammation and alterations in the cytokine profiles 
of afflicted individuals, which in early life gives rise to SZ 16. 
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1.2 THE IMMUNE SYSTEM AND THE INFLAMMATORY RESPONSE 
The human body benefits from a complex repertoire of molecular and cellular mediators of 
defense mechanisms against invading pathogens. An activation of host defense system is often 
accompanied by inflammation, a humoral and cellular mediated response to pathogenic 
material, irritants, toxins and traumatic breach of membranes. The purpose of the initial 
inflammatory response is to eliminate the invading pathogen or irritant and begin the process 
of repair. The acute inflammatory response and ongoing inflammation is highly regulated by 
the human body as chronic or unchecked inflammation is associated with many somatic 
disorders17. In SZ, there is a growing consensus for inflammation to be elevated above 
physiological levels. The reasons for this are manifold, including unchecked chronic 
inflammation likely caused by an interaction between the host’s genetic background, and 
exposure to foreign pathogens, or toxic by-products of lifestyle factors, such as smoking or 
alcohol abuse. In a meta-analysis, drug-naïve first-episode psychosis (FEP) patients were found 
to have higher levels of interleukin-1β (IL-1β), IL-6, tumor necrosis factor alpha (TNF-α) 18 
and cardio-metabolic disturbances 19-21. C-reactive protein (CRP), a canonical circulating 
indicator of inflammation has also been found to be elevated in SZ 22. Peripheral inflammation 
has been implicated in the activation of inflammatory networks in the central nervous system 
(CNS) 23. And, conversely, immune activation in CNS, in particular chronic microglial 
activation, is proposed to be a source of inflammation in peripheral blood; perinatally primed 
subsets of microglial cells have been suggested to release pro-inflammatory cytokines to the 
periphery24. Correspondingly, increased levels of pro-inflammatory cytokines and kynurenine 
metabolites were found in the cerebrospinal fluid and in the serum of chronic SZ patients in 
independent investigations 25,26. In this thesis, mediators of inflammation based on existing 
literature, were investigated in blood samples from patients with psychosis27-33. The mediators 
for inflammation were noted for their attributes of neurotrophicity and previous reports of 
alterations in cohorts of psychotic disorders (Figure 1). 
 
Figure 1: Mediators of inflammation were selected based on having neurotrophic characteristics, having been 
reported in the literature as being altered in patient material of psychotic disorders and being involved in immune 
regulation. Individual hypotheses were constructed for CRP, IL-1β, IL-2, IL-22, IL-2Rα, IL-12p40 and IFNγ that 
they would be dysregulated in patients of psychotic disorders. In addition, IL-6, IL-10, IL-17A, IL-18, Eotaxin-1, 
MCP-1, TNFα, TRAIL were investigated to confirm previous reports of alterations in patients of psychotic 
disorder as well as for their defined roles in immune regulation. Little is known on the alterations of fractalkine 
and GRO-α in the context of psychotic disorders, while VEGF-A is at the intersection of all 3 research spaces of 
this study. 
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1.3 MITOCHONDRIAL DYSFUNCTION 
The mitochondrion is a highly dynamic subcellular organelle involved in the production of 
ATP which powers the cell. Mitochondrial dysfunction through environmental stressors34 or 
hereditary factors35 have been implicated in various somatic and neurodegenerative disorders 
25,36,37 and in small patient groups of bipolar disorder (BD) and SZ 38,39. Mitochondrial 
dysfunction and associated by-products, such as Reactive Oxygen Species (ROS) are 
implicated in caspase activation40, inflammasome recruitment41 and the activation of 
downstream cytokines and  inflammatory mediators42 which can ultimately lead to increased 
CNS localized apoptosis and neurodegeneration. Mitochondrial dysfunction is associated with 
an increased presence of ROS superoxide anion (O2
−). O2
− is responsible for the activation of 
redox-sensitive transcription factor and primary tissue inflammation regulator nuclear factor-
κB (NF-κB) which in turn causes an increase in the expression of cytokines, chemokines, 
eicosanoids, inducible nitric oxide synthase (iNOS) and adhesion molecules43,44(Figure 2). 
Therefore, the mitochondrial health of SZ patients has been subject to increasing scrutiny with 
the aim to characterize mitochondrial abnormalities in SZ and BPD patients versus normal 
healthy controls. In the striatum of SZ subjects, treatment responsive patients had 40% decrease 
in synaptic mitochondrial density in the caudate nuclease and putamen compared to healthy 
controls45. Mitochondria were noticeably smaller in the prefrontal cortex (PFC) of BPD 
patients compared to healthy controls46. Oligodendrocytes in the PFC of SZ patients showed 
remarkable reductions in mitochondrial numbers and volume47. In a comparative analysis of 
white blood cell mitochondria between SZ and healthy controls it was found that SZ patients 
had fewer mitochondria which showed swelling and fragmentation of the cristae48. The hyper-
oxidative states and chronic inflammation brought about by psychiatric illnesses create a closed 
loop between mitochondrial dysfunction and inflammation creating a vicious cycle of events44 
which may explain the accelerated ageing and multifaceted co-morbidities experienced by SZ 
patients 49. One method of investigating mitochondrial functionality, which can be applied to 
cohorts of psychotic disorders, was reported by Lee and Wei50, where mtDNA copy number is 
investigated as a proxy for mitochondrial biogenesis and mitochondrial functionality. Using a 
real time polymerase based method of quantifying DNA, mtDNA copy number from patient 
leukocytes can be measured in patients in a non-invasive way51. 
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Figure 2: The mitochondria is a highly dynamic organelle which interchangeably exists as a discrete organelle and 
a part of a sub-cellular vesicular network, depending on cellular bioenergetics, stress and exposure. Multiple copies 
of the mitochondrial DNA exist within the mitochondrion, which is replicated upon mitochondrial fission. 
Measuring the copies of mtDNA has been used as a sensitive measure of mitochondrial health and functionality 
in the context of psychotic disorders. This method has been refined and used for the purpose of Paper I of this 
thesis. 
1.4 GDF-15 
Apart from directly measuring mitochondrial morphology and volume or proxy measurements 
such as mtDNA content, a group of researchers have linked mitochondrial dysfunction and 
diseases to the upregulation of an all-cause mortality marker called Growth differentiation 
factor-1552,53. GDF-15 has been characterized to be a novel biomarker for diagnosing 
mitochondrial disorders and tracking the treatment outcome of pyruvate therapy in 
mitochondrial disease 52. GDF-15 is a member of the transforming growth factor- β (TGF-β) 
superfamily of cytokines, which is upregulated in response to injury, with defined roles in 
regulating inflammation and apoptosis54. It is suggested to have an overall anti-inflammatory 
effect and is elevated in cancer, cardiovascular disease (CVD) and obesity, as a compensatory 
mechanism 33,55. In CNS GDF-15 is upregulated in response to injury such as cold-induced 
lesions in vivo with an additional role as a neurotrophic factor 56. Strelau et al have reported 
that GDF-15 is neurotrophic and neuroprotective in neurons in vitro and in vivo where 
intoxicated dopaminergic neurons of the 6-hydroxydopamine rat model of parkinsonism are 
rescued, thus abolishing an abnormal turning behavior 57. Interestingly, a proteomics 
investigation for biomarker development conducted by Frye et al., has returned GDF-15 as a 
putative biomarker for mood disorders. In this study however, patients with BD type I, BD type 
II, but not patients with SZ, were investigated. Plasma levels of circulating GDF-15 in patients 
relative to controls were reported without exploring correlation to psychosis severity 58. 
Moreover, in the context of psychiatric illness, the association between circulating GDF-15, 
CRP and the influence of metabolic comorbidities is unknown.  
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1.5 CARDIOVASCULAR RISK IN PATIENTS WITH PSYCHOTIC DISORDER 
 
CVD risk factors such as diabetes, intermediate stages of hyperglycemia that exist between 
diabetes and normal glucose homeostasis, smoking, obesity and the metabolic syndrome are 
common in patients with schizophrenia and other types of psychosis 59,60. Second generation 
antipsychotics (SGAs) are significantly associated with weight gain, insulin resistance, 
diabetes, dyslipidemia and increased cardiovascular risk61. Furthermore, clozapine is directly 
associated with cardiotoxicity62,63. 
 
Clinical risk scores combined with biomarkers related to increased cardiovascular risk have 
been implemented in clinical practice in the general population. The combination has also 
proven useful in elderly patients64. Several risk scoring systems, such as the Framingham risk 
score (based on age, sex, smoking, diabetes, cholesterol and blood pressure levels), have been 
used65. The Reynolds Risk Score uses CRP and family history in addition to the conventional 
risk factors included in the Framingham risk score66. Studies have shown that the RRS 
significantly improved fit compared with either the Framingham-based Adult Treatment 
Panel guidelines III, CHD risk score or the newer Framingham CVD score67.  
 
Recent studies indicate that biomarkers reflecting blood vessel wall stress, myocardial cell 
damage and inflammation improve the estimate of CVD risk68,69. N-Terminal Pro-B-Type 
Natriuretic Peptide (NT-proBNP) and high-sensitive troponin T (hs-cTnT) have been shown 
to be useful in estimating cardiovascular risk in patients with type 2 diabetes 70. NT-proBNP 
is predictive of incident CVD both in cohorts comprised of generally healthy individuals and 
in cohorts of high-risk individuals71. Hs-cTnT is specifically predictive of coronary heart 
disease (CHD). In the efforts made to identify markers that indicate increased CVD risk in 
healthy individuals, high-sensitive C-reactive protein (hsCRP) appears to be promising 72. 
The use of hsCRP as a test to identify high risk patients has been evaluated in numerous 
studies. Among patients with non-affective psychosis hsCRP has previously been shown to 
be associated with increased risk of metabolic syndrome, high triglyceride levels and larger 
waist circumference73.  
 
The presence of psychotic symptoms, the core of severe mental illness, takes health care’s 
focus away from somatic symptoms and disease. Patients with severe mental illness like 
schizophrenia are also less likely to seek medical care, even during acute symptoms of CHD 
74. Somatic symptoms may therefore be underdiagnosed and less monitored, potentially 
contributing to the increased mortality in patients with mental illnesses75. Broadening the 
focus of treatment in psychotic disorders to include somatic illness and cardiovascular risk 
factors with close monitoring of blood-pressure, fasting glucose and potentially the use of 
biomarkers might decrease the mortality. 
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Figure 3: CVD is complex disorder which develops in the patient due to various extrinsic and intrinsic factors. 
Beginning with a genetic predisposition as indicated by genetic markers or a family history of CVD, the condition 
can be exacerbated by lifestyle and environmental factors such as smoking, a sedentary lifestyle, a high fat or 
sugary diet, alcohol or substance abuse. This translates to elevated CVD clinical risk markers such as the presence 
of obesity, raised LDL, lowered HDL, raised triglycerides, increased blood pressure, presence of diabetes or 
hyperglycemia along with increased levels of canonical and novel markers of CVD. In the next phase sub-clinical 
CVD diseases such as carotid intima-media thickening (IMT), coronary calcium aggregation and endothelial 
dysfunction occur. Finally these factors in combination give rise to bona-fide CVD. 
1.6 PHYSICAL ACTIVITY AS AN INTERVENTION IS PSYCHOTIC DISORDER 
Cognitive decline is prevalent in patients with SZ76 and BD77. Physical activity as a prophylaxis 
against cognitive decline and dementia is well supported by individual studies and has started 
to gain currency in the clinic as a treatment against mild cognitive impairment. In a follow up 
study of more than 6000 eligible subjects aged 65 years and older, physical exercise was 
associated with lower risk of cognitive impairment. Additionally, there was also a lowered risk 
for Alzheimer’s disease. Both effects were significant after being age, sex and education level 
adjusted78.  In another study which looked at elderly women and the effects of physical activity 
on cognitive decline it was reported that after adjustment for age, educational level, comorbid 
conditions, smoking status, estrogen use, and functional limitation, women in the highest 
quartile of physical activity remained less likely than women in the lowest quartile to develop 
cognitive decline79. Clinical intervention in cases of mild cognitive impairment involve an 
encouragement towards lifestyle changes that include an increase in physical activity 80. 
Physical activity intervention in SZ patients has been shown to improve cardio-respiratory 
fitness there is however little known about the effects on the cognitive function and function in 
daily life81. Exercise itself has potential benefits for those affected by psychosis, and has shown 
no evidence of harm in systematic reviews and meta-analyses82,83. Apart from the 
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cardiovascular benefits of exercise84 , the anti-inflammatory effects of exercise85 and general 
systemic effects of exercise86,  are well founded (Figure 4). 
 
 
Figure 4: Physical exercise’s benefits are manifold.  Systemically it helps to alleviate age related ailments such as 
osteoarthritis, osteoporosis, dementia and maintains vascular health87. Physical exercise protects against Diabetes 
type II, lowers glycated hemoglobin (HbA1C) levels, increases insulin sensitivity88. Physical exercise maintains 
bone density, lowers BMI, increases aerobic capacity, increases oxidative phosphorylation and promotes 
mitochondrial biogenesis86. In addition to this hypertension is avoided by lowering systolic and diastolic blood 
pressure89. Through physical exercise dyslipidemia can be regulated, where triglyceride levels are reduced and 
HDL/LDL ratio increased90.  Physical exercise attenuates inflammation, excessive ROS production, attenuates 
pro-inflammatory cytokines and reduces CRP levels85. Physical exercise improves cardiac function through 
increasing cardiac output and stroke volume91. Cardiac protection is afforded by physical exercise by reducing the 
chance for ischemic reperfusion injury92. Plaque progression and re-stenosis is slowed down which helps protect 
against macrovascular coronary artery disease93. Cardiovascular healthy is promoted by improved vasoreactivity, 
endothelial function, Ca2+ handling and blood vessel collateralization94. Cardiac metabolism is improved through 
better oxidative phosphorylation and mitochondrial biogenesis95. 
 
 
 
“A journey of a thousand miles must begin with a single step.” 
“Everything has its beauty, but not everyone sees it.”  
- Confucius
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2 AIMS 
The overall aim of the thesis was to identify novel molecular blood markers of psychosis. 
The specific aims of each constituent study in the thesis are listed below: 
2.1 STUDY I 
To determine if mitochondrial DNA (mtDNA) copy number was associated to severity of 
psychotic illness, exposure to specific antipsychotic drugs, and degree of metabolic 
comorbidity in psychosis patients.  
2.2 STUDY II 
To determine if plasma Growth Differentiation Factor-15 (GDF-15) levels were different in 
psychosis patients compared to healthy controls, associated with age, severity of psychotic 
illness, and with degree of metabolic comorbidity and CRP levels in the patients.  
2.3 STUDY III 
To investigate the profile of plasma GDF-15 levels in comparison to clinical cardiovascular 
disease (CVD) risk factors and established CVD biomarkers and C-reactive protein.  
2.4 STUDY IV 
To investigate markers of immune activity in first episode psychosis (FEP) patients at baseline 
and changes over 12 weeks of physical exercise, and relate that to baseline clinical 
characteristics and amount of exercise. 
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3 MATERIALS AND METHODS 
3.1 THE SWEDISH STUDY FOR METABOLIC RISK IN PSYCHOSIS 
The Swedish study for metabolic risk in psychosis (SMRP) aimed to investigate the presence 
and causes of metabolic comorbidities in patients of psychosis. Participants in the studies in 
this thesis were recruited between 2005 and 2009 at outpatient clinics for psychosis treatment 
mostly within Stockholm County. Blood samples and clinical data such as body weight, height, 
BMI, waist circumference, fasting glucose levels, blood lipid profile, cholesterol, HDL, LDL 
were collected. Patients were queried on alcohol and tobacco use, previous clinical diagnoses, 
and psychosis severity using the Clinical Global Impression-Severity (CGI-S) index96 
functioning using Global Assessment of Functioning scale97, general health status, family 
history of diabetes, medication and dosage. Medications and diagnoses were confirmed in 
medical records. Ethical permits for the use of clinical samples were obtained from the regional 
ethics review. 
3.2 THE FIT FOR LIFE STUDY 
The Fit for life study was conducted in Stockholm, Sweden. Patients with first episode 
psychosis (FEP) were approached at three psychiatric outpatient clinics specialized in the 
treatment of FEP in young adults, ages 18-45 years. Each clinic served approximately 200 
individuals, most of whom were diagnosed with SZ. To participate, individuals had to be 
formally diagnosed with a psychotic disorder and receiving specialist care for FEP with at least 
one documented episode in the preceding five years. At the time of referral to the specialist 
clinic they must also have been under 40 years of age. Volunteers were excluded if they were 
deemed too sick to participate by the individual’s clinician or had a history of CVD or physical 
injury that would make physical exercise unsuitable or unsafe. Patients were recruited through 
advertisement posters placed in common areas of the clinics. Once the individual had registered 
their interest in participating, their details were passed to a research nurse coordinating 
recruitment. Eligibility of participants was confirmed at a short interview where they were 
provided with information through written and verbal communication. Baseline information 
and written consent were then obtained. Physiological measurements were taken at baseline 
and within one week after the last exercise session at the Swedish School of Health and Sports 
Medicine (GIH) by research assistants. Each individual was requested to attend 3-5 sessions 
per week for the duration of the 12-week program. Each session entailed a brief warm-up 
lasting 5-10 minutes before an intensive 50-minute workout focusing on resistance training and 
cardiovascular fitness, followed by stretching, with a total duration of approximately 1 hour. 
Due to the nature of the patient cohort small group sessions tailored to the capability and fitness 
of the participants were organized. Sessions were individualized to cater to participant 
requirements and thus maximize attendance.  Some patients expressed difficulties with specific 
exercise tasks, group sizes, or exercise setting. The exercise regime adhered to the American 
College of Sports Medicine consort agreement on prescription of exercise as an effective 
intervention98. All sessions were conducted by trained instructors at GIH being final semester 
students of the health coaching bachelor program conducted at GIH. This program is a three-
year education in sport science, public health and includes both scientific and sports research. 
The Borg scale99, an estimation of the pulse rate, was used by trainers during the session to 
monitor and adjust the exercise intensity for the individual. Trainers also maintained contact 
with participants throughout the study contacting them via SMS or phone prior to most 
sessions. 
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3.3 HEALTHY CONTROLS 
In Paper II and Paper IV analyte levels in samples from psychosis patients were compared to 
levels in samples from healthy controls. In Paper II the healthy controls had no severe 
psychiatric disorder and were selected to have similar distribution of age, gender and BMI as 
the psychosis patients studied. All subjects had normal glucose tolerance and a family history 
of diabetes corresponding to the population average in Sweden. In Paper IV, the healthy 
controls had no psychiatric diagnosis and were selected to have similar distribution of age, 
gender as the psychosis patients studied. The healthy control samples had been collected and 
stored the same way as the psychosis samples they were compared to. 
3.4 DNA EXTRACTION AND MITOCHONDRIAL DNA COPY NUMBER 
ANALYSIS 
Venous blood was collected from patients in SMRP and DNA was extracted using a standard 
phenol-chloroform method 100 followed by desalting using Illustra NAP-5 columns (GE 
Healthcare, Buckinghamshire, UK).  DNA was quantified spectrophotometrically using  
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). 
Mitochondrial DNA copy number per copy of nuclear genome (i.e. per cell) was determined 
using real-time quantitative PCR (qPCR) as per Rooney JP51  and Venegas V 101 protocol. 
Relative amount of the mitochondrial gene tRNA-Leu(UUR), to nuclear single-copy gene β2-
microglobulin (B2M) (mtDNA copy number) was determined by standard curve. Briefly, each 
DNA sample (4.0 ng) was assayed for tRNA-Leu(UUR) and B2M within the same 384-well 
plate, in triplicates. DNA was amplified by using Power SYBR Green in 10 µl reaction volume, 
in total. The reaction was performed using QuantStudio 7 Flex (Applied Biosystems, Waltham, 
MA, USA). The following conditions were used: 95°C for 15 min, followed by 40 cycles of 
95°C for 15 s and 60°C for 1 min, followed by a dissociation stage to control for amplification 
specificity. Identical standard curves of control genomic human DNA (Applied Biosystems) 
ranging from 10 ng to 0.016 ng, was run on each plate for both genes. This was used to 
determine the quantity of each gene for each sample thus controlling for differing amplification 
efficiencies between mtDNA and B2M. Gene amplification product quantities were used to 
determine the M/S ratio for each sample. Amplicons with a Ct value outside the standard curve 
or a Ct standard deviation of ≥ 0.3 between triplicate or were excluded from the analyses. 
Patient samples were assayed in 12 consecutive qPCR plates. R2 coefficients of standard curves 
were greater than 0.99 for each primer set in 384-plate. The inter-plate coefficient of variation 
(CV) of M/S ratio was 8.3%. This was calculated as a mean from three inter-plate control 
samples run in the 12, 384-well plates. The mean intra-plate CV of M/S ratio of the three control 
samples in triplicates was 4.6%. The mtDNA analysis detection success rate was deteremined 
to be a 100%. As a precaution, primer binding regions were selected for low deletional <3%102 
or mutational (SNPs) exposure 2.2%103. A literature and mtDNA database search revealed that 
no known psychiatry related SNPs are present in the primer binding mtDNA regions (Online 
Mendelian Inheritance in Man, OMIM®104 and www.mitomap.org103). The probability of 
random somatic mutations occurring at the selected primer binding regions is determined to be 
0.24%.  For a subset of the patients an alternative amplicon in the D-loop region of the 
mitochondrial genome was targeted for the quantification of mtDNA for the confirmation of 
the sensitivity of the assay. The D-loop region was  selected based on Bai and Wong 102 and 
was designed from mtDNA sequences that do not contain reported mutations or 
polymorphisms occurring in more than 1.6% of the population 
(http://www.genpat.uu.se/mtDB/Polysites103,105). The D-loop region has been used for mtDNA 
content analysis in similar investigations for the quantification of mtDNA copy number 
(cn)106,107. mtDNAcn measurements targeting the D-loop and tRNA-Leu(UUR) in the same 
samples were compared  and found to be highly correlated, n = 55, r = 0.996, p = 1.62E-58.  
The primer sequences were (written 5’3’): mtDNA Fw: CAC CCA AGA ACA GGG TTT 
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GT; mtDNA Rv:  TGG CCA TGG GTA TGT TGT TA; B2M  Fw: TGC TGT CTC CAT GTT 
TGA TGT ATC T ; B2M Rv: TCT CTG CTC CCC ACC TCT AAG T. Alternative primer 
binding region in D-loop of mitochondrial genome (written 5’3’): D-loop Fw: CAT CTG 
GTT CCT ACT TCA GGG; D-loop Rv :TGA GTG GTT AAT AGG GTG ATA GA. The 
success rate of mtDNA copy number measurement was 97% (594/614 samples). mtDNA copy 
number was corrected for platelet and leukocyte count. These variables are known to affect MS 
ratio as platelets have mitochondria and accompanying mtDNA but no nuclei and hence lack a 
nuclear genome, which results in an overestimation of mtDNA108. Whole blood derived 
mtDNA are associated with leukocyte count as reported by several groups and thus a correction 
for the platelet and leukocyte have been suggested as a refinement to the mtDNA copy number 
measurement108-110. 
3.5 SINGLEPLEX AND MULTIPLEX ELISA 
Plasma samples from SMRP were assayed for GDF-15 protein levels with the Quantikine® 
Singleplex ELISA Human GDF-15 immunoassay (R&D Systems) according to the 
manufacturer’s instructions. A subset of the samples were assayed with technical replicates. 
The optical density of sample wells was determined using the Microplate Reader by Thermo 
Labsystemsm Inc, and the sofware Multi-skan AscentTM for processing the data. The GDF-15 
concentration of each sample was calculated using the measured absorbance against a standard 
curve. All samples had been freeze-thawed only once prior to analysis and all samples were 
run within the same week 
For the purpose of tracking inflammatory profile of FEP patients in the Fit for Life study 
(Paper IV) 18 analytes (C-Reactive Protein (CRP), Eotaxin-1, Fractalkine, Gro-α, Interferon-
γ (IFN-γ), interleukin (IL)-10, IL-12 subunit p40 (IL-12p40), IL-17A, IL-18, IL-1β, IL-2, IL-
22, Interleukin-2 receptor subunit alpha (IL2Rα), IL-6, monocyte chemoattractant protein 1 
(MCP1), tumor necrosis factor alpha (TNFα), TNF-related apoptosis-inducing ligand (TRAIL) 
and Vascular endothelial growth factor (VEGF) were assayed in 49 patient plasma samples 
drawn at baseline and follow-up and 42 healthy control plasma samples drawn at baseline 
(since no exercise intervention). The V-plexTM   vascular injury panel 2 human kit was used to 
measure CRP in plasma. The U-plexTM multiplex ELISA system was used to measure Eotaxin-
1, Fractalkine, Gro-α, IFN-γ,  IL-10, IL-12p40, IL-17A, IL-18, IL-1β, IL-2, IL-22, IL2Rα, IL-
6, MCP1, TNFα, TRAIL, VEGF. The U-plex system is limited to 10 analytes per plate and 
requires compatibility for the analytes to be tested in the same run to avoid antigen antibody 
cross-reactivity. Thus 2 plate configurations were used to cover the 17 analytes being tested. A 
10-plex ELISA was used to assay Fractalkine, Gro-α, IFNγ, IL-10, IL-12p40, IL-17A, IL-1β, 
IL-2, IL2Rα, IL-6 and a 7-plex ELISA was used to assay Eotaxin-1, IL-18, IL-22, MCP-1, 
TNF-α, TRAIL and VEGF.  
Both high sensitive multiplex enzyme-linked immunosorbent assay (ELISA) systems were 
developed by Meso Scale Diagnostics (MSD), Gaithersburg, Maryland, USA. ELISA was 
performed according to the manufacturer’s instructions using provided instruments and the 
MSD software Discovery Workbench version 4.0. All plasma samples had been freeze-thawed 
twice. The patient plasma samples and the manufacturer-delivered standard curve samples and 
calibrators were measured in duplicates, and analyte-specific intraplate coefficients of variation 
(CVs) were determined from the standards and calibrators. Samples at baseline and follow up 
from each patient were measured in the same plate to reduce variability. All standard curves 
had a robust correlation (R2>0.999). The healthy controls were measured in singlets as intra-
plate CVs were small in all previously measured samples (<5%). Inter-plate CVs were < 13% 
for all analytes. Inter-plate CV for VEGF was 12.8%, IL-18 was 12.0%. Eotaxin-1, IL-17A, 
IL-10, IFN-γ, MCP-1, IL-22, TNF-α and TRAIL registered inter-plate CVs between 5-10%. 
The rest of the analytes had interplate CVs < 5%. For the purpose of statistical analysis, analytes 
 14 
with signals below the level of detection (LLOD) were set to zero (concentration corresponding 
to blank signal) in accordance to previously published methods111.  Data is presented as 
calculated mean values of undiluted plasma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“The old pond; 
A frog jumps in — 
The sound of the water.” 
- Basho 
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4 RESULTS AND DISCUSSION 
In this section the essence of the major results and points of discussions of the constituent 
papers are presented and discussed.  A more detailed and comprehensive description can be 
found in the papers and manuscripts appended to this thesis.  
4.1 MITOCHONDRIAL DNA COPY NUMBER IN PATIENTS WITH CHRONIC 
PSYCHOTIC DISORDER (PAPER II) 
Mitochondrial DNA is vulnerable to the ubiquitous nitrosative and oxidative free radicals 
present within the mitochondria. Previous reports of mitochondrial dysfunction and mtDNA 
depletion in psychotic disorders112, led us to the investigation of mtDNA copy number in whole 
blood extracted leukocyte DNA113,114. MtDNA copy number per cell was estimated after 
correction for leukocyte count and platelet count, an important consideration as (i) platelets 
have mitochondria and accompanying DNA but no nuclear DNA, (ii) number of platelets and 
leukocytes vary between individuals, and (iii) some antipsychotic treatment has been shown to 
be toxic to white blood cells115. Additionally, to account for loss of signal due to deletion events 
in the mtDNA102, the selection of genes or mtDNA regions to be analyzed were based on the 
frequency of deletion events taking place in selected regions, obtained from mtDNA databases 
and existing literature, thus, regions resistant to major known deletion events were 
chosen116,117. Paper I is one of few studies to have taken into account the above technical 
considerations where mtDNA copy number research in the material of patients of psychotic 
disorders is concerned. A uniformly applied methodology similar to the above will ensure that 
individual studies may be compared to each other and represent the true quantity of mtDNA 
copy number in patient material. 
4.1.1 Mitochondrial DNA copy number depletion is associated with the use 
of clozapine and risperidone 
Independently of the psychosis severity of the patient, we found that the use of clozapine and 
risperidone amongst other anti-psychotic treatment elicited a similar depletion effect on 
mtDNA. The effect was dose dependent as patients’ prescribed dosage of clozapine and 
risperidone was associated with mtDNA copy number. For clozapine, Spearman’s ρ was = -
0.351, p<0.01, n = 61 and for risperidone Spearman’s ρ was = -0.233, p<0.05, n = 91. 
Interestingly for those patients on clozapine and risperidone the proportion of life on treatment 
was the best predictor of mtDNA copy number (β=-0.215 and p < 0.05) This further confirms 
the distinct effect of clozapine and risperidone we saw on mtDNA copy number in our patient 
cohort. In our analysis we had an acceptable statistical power to detect an effect of other anti-
psychotic drugs where patient cohorts were larger than 40, such as olanzapine n=108 and 
aripiprazole n=73 but no such effect was found.  
For patients on other types of anti-psychotic treatment, age and psychosis severity were the 
best predictors of mtDNA (βCGI-S=-0.129 and p < 0.05, βAge=-0.159 and p < 0.01). For psychosis 
severity estimation we relied on the routinely used the CGI-S index, which was adapted to be 
used in the setting of psychosis outpatient clinics. This symptom based adaptation of CGI-S is 
possible as the clinicians are encouraged to use the patient cohort as a reference group96. In the 
context of psychosis CGI-S has shown to have considerable overlap with severity scales which 
are tailored for psychotic disorders such as SZ118. 
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4.1.2 Mitochondrial DNA copy number reduction in human neurons 
A further step we took in Paper I was to assess whether the effect of clozapine and risperidone 
found on mtDNA copy number in whole blood also was detectable in human neurons from 
NESCs. The neurons were established to have similar morphological and electrophysiological 
characteristics as human neurons in vivo 119,120. Human neurons when treated in cell culture 
medium with pharmacological doses of clozapine simulating target CSF levels exhibited a 16% 
reduction in mtDNA copy number compared to vehicle treated cells (p<0.01). Human neurons 
which were treated with risperidone at target CSF levels did not experience any effect. 
However, at target plasma concentrations, there was an estimated 14% reduction in mtDNA 
copy number in the human neurons exposed to risperidone and 25 % reduction in mtDNA copy 
number for human neurons exposed to clozapine. 
4.2 PLASMA GDF-15 LEVELS ARE ELEVATED IN PATIENTS OF CHRONIC 
PSYCHOTIC DISORDER (PAPERS II AND III) 
Currently, elevated plasma GDF-15 levels has been reported in a CVD and metabolic 
disorders121,122. In the context of unipolar depression, depression with BD I and BD II, it has 
been reported that GDF-15 levels are statistically different between the groups58, however 
much less information is available of GDF-15 in the context of psychotic disorders. In paper II 
we analyzed patient plasma for GDF-15 in n=120 patients of psychotic disorder and made a 
comparison to age and gender matched healthy controls. We found that there was a significant 
elevation in plasma GDF-15 levels in patients, median of patients=744 ng/mL, median of 
controls=516 ng/mL, p<0.001. We further analyzed GDF-15 for association to several clinical 
variables which reflected the severity of the psychosis, metabolic comorbidity and lifestyle 
factors and found GDF-15 to be associated with gender and smoking, where men had increased 
levels of GDF-15 (p<0.05) and smoking was associated with increased plasma GDF-15 levels 
(p<0.01). 
4.2.1 GDF-15 is robustly correlated with age in patients of chronic psychotic 
disorder (Paper II) 
GDF-15 was robustly associated with age in the patients (Spearman’s ρ = 0.496, 
βStandardized = 0.494, p < 0.001). GDF-15 has been reported to be an all-cause mortality marker123 
and well described for age dependent reference limits with prognostic relevance124. Confirming 
that such a robust association exists with age in the presence of psychotic disorder is important 
information for assessing the usefulness of GDF-15 as a biomarker in the context of psychotic 
disorders. The presence of age dependent reference limits opens up the possibility for testing 
the biological age of patients of psychotic disorders when taken together with other biomarkers.  
4.2.2 GDF-15 levels are associated with psychosis severity as measured by 
CGI-S 
Psychosis severity as measured by CGI-S was negatively associated with GDF-15 levels 
(βstandardized = −0.221, t = −2.58, p = 0.012). This observation resonates with the anti-
inflammatory function of GDF-15. A growing body of evidence suggests that inflammation is 
involved in the aetiology of psychosis32,125-128. Thus, the depletion of anti-inflammatory agents 
such as GDF-15 may lead to more severe psychosis symptoms or poorer functionality.  
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4.2.3 Cardiac biomarkers for patients with chronic psychosis (Paper III) 
Description of CVD risk markers in a patient cohort of psychotic disorder reveals a latent risk 
of CVD. The elevated risk of CVD in patients of psychosis has been well established and is 
often the cited reason for early mortality in these patients61,74,129. In mental health disorders 
such as psychotic disorders, the focus on treating the psychiatric symptoms often takes away 
the attention from the potential somatic comorbidities such as metabolic syndrome and CVD 
arising from genetic and environmental factors. Thus, in Paper III we sought to address the 
gap in CVD risk monitoring in psychosis patients using the SMRP patient cohort by 
investigating levels of three established CVD biomarkers as well as the putative CVD risk 
marker, GDF-15, in relation to frequency of elevated levels and association to other established 
clinical markers of CVD risk. We show that our study cohort of patients with psychotic 
disorder, similarly to other psychosis cohorts, had an elevated risk for CVD as 36% had 
clinically elevated hs-CRP levels, 8% had pathological hs-cTnT levels, and 7% had 
pathological NT-proBNP levels, indicating latent and undiagnosed CVD. Also, based on 
published healthy control reference values124 we saw that 25% of the cohort had elevated GDF-
15 values. 
4.2.4 GDF-15 resembles more closely a cardiac biomarker than acute 
inflammation 
In bivariate correlation analyses we saw that GDF-15 was correlated with both NT-proBNP 
(Kendall’s tau-b=0.171, p<0.01) and hs-cTnT levels (Kendall’s tau-b = 0.312, p<0.01), but not 
with hs-CRP. This could be an indication of GDF-15 to more closely resemble a cardiac 
function marker than a marker of inflammation such as hs-CRP. However, GDF-15 levels were 
not associated with clinical CVD risk factors including descriptors of metabolic health, such 
as, systolic pressure, blood lipids, fasting glucose or waist circumference. Variance of hs-CRP, 
NT-proBNP and hs-cTNT levels as dependent variables in linear regression analysis were 
better explained by metabolic health descriptors than was the variance in GDF-15 levels. 
However, the GDF-15 level variance could be best explained of the four, due to the robust 
dependence on age, which in itself is an interesting observation. As observed in Paper II GDF-
15 levels were elevated in patients of psychotic disorders compared to age and gender matched 
healthy controls, while in Paper III the data propose that this elevation might be explained by 
latent CVD as GDF-15 levels which correlated well with hs-cTnT levels130, which is reflected 
as accelerated ageing in vivo by plasma GDF-15. 
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4.3 EXERCISE INTERVENTION IMPROVES FITNESS AND INFLAMMATION 
PROFILE IN FIRST EPISODE PSYCHOSIS PATIENTS 
Paper IV was a study which took place in the context of the “Fit for Life” study131-133 which 
aims to complement clinical treatment of psychosis with exercise intervention, with a particular 
focus on mitigating the ill effects of a sedentary lifestyle134 and social isolation that patients of 
psychosis often experience135.  As a result of the intervention patients’ experienced improved 
levels of cardiorespiratory fitness, 27% of the cohort attained the VO2 max level prescribed for 
their age and gender. In addition to this, CRP was reduced over the intervention (Mean ΔlnCRP 
= -0.36, SD ΔlnCRP = 1.04, t = -2.37, p = 0.02), although still elevated post-intervention 
compared to healthy controls (p<0.01).   
4.3.1 Fractalkine levels are elevated in First Episode Psychosis 
In paper IV, we made a novel observation that plasma soluble fractalkine levels were elevated 
in patients with FEP when compared to age and gender matched healthy controls. Apart from 
general improvements in fitness and inflammation profile, reduction in fractalkine levels in the 
patient cohort can be viewed as a clinical gain for the patients undergoing the above 
intervention, when considering fractalkine’s role in inflammation. Fractalkine is a ligand for 
CX3CR1 and integrins136.  Membrane bound fractalkine is cleaved by metalloproteinases, 
induced by TNFα, into a soluble ligand form of fractalkine137 which is chemotactic to cellular 
mediators of immunity such as  T-cells, microglia and monocytes138. CX3CR1 the cognate 
receptor of fractalkine is expressed by microglia, potentially to receive activating signals in the 
form of soluble fractalkine released by neurons (Figure 5). Systemically fractalkine is 
expressed by vascular endothelial cells induced by a Th1 cytokine profile137,138 which allows 
cellular mediators of immunity to extravasate between vascular endothelial cells along a 
chemokine gradient to be recruited to sites of inflammation. 
 
Figure 5: Cell types in regions of CNS and PNS of mice indicated and grouped as a tree diagram. Expression of 
fractalkine (CX3CL1) is indicated by lower blue bar, present across most neuronal cell types, especially those 
localized in the cortex, hippocampus and di-/mesencephalon. Fractalkine expression is absent immune cells. 
Conversely, the cognate receptor for fractalkine CX3CR1 expression is absent in neuronal subsets and richly 
present in immune cells. Neuronal signaling and activation of microglia could be regulated by fractalkine. Graphic 
generated on http://mousebrain.org/genesearch.html.. 
Raw data available on https://www.ncbi.nlm.nih.gov/sra/SRP135960 
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4.3.2 Subgroups defined by changes in fractalkine 
The present study showed that plasma fractalkine is significantly elevated at group level in 
those with FEP compared to healthy controls (p<0.01). While 34.7% of the FEP were at 
fractalkine level seen in healthy controls, the remaining 69.4% (n=34) had fractalkine levels 
far above those reported for sepsis and after induction by intravenous injection with 
lipopolysaccharide (4 ng/kg)139. The FEP patients were found to further categorize into 
fractalkine level-defined groups by exploring the response to structured exercise for 12 weeks. 
While all FEP patients grouped together showed a reduction in plasma fractalkine by the 
intervention (median ΔsFKN, -295 pg mL-1), p<0.05, repeated measures ANOVA (RMA)), 
reflecting a potential anti-inflammatory effect of physical exercise140 , four fractalkine response 
groups were identified where the fractalkine level could be represented by either ‘on’ or ‘off’ 
at baseline/follow-up: stably low fractalkine levels (off/off, n=12), responders (on/off, n=20), 
non-responders (on/on, n=12) and reverse responders (off/on, n=5). 
 
4.3.3 Those with reduced fractalkine levels after exercise intervention had 
less severe psychotic disorder at baseline 
Fractalkine response was tested for association with baseline clinical parameters and drug 
treatment. Fractalkine responders had a shorter time since first psychiatric contact (χ2 = 11.83 
(3 df) p = 0.008). Accordingly, time since first psychiatric contact associated with change in 
plasma fractalkine level also when adjusting for sex, age and use of antipsychotic drug [yes/no] 
(p=0.02). ASD and ADHD comorbidity was present in 26.2% of patients and was more 
common among fractalkine responders 43.8%. Reduction in plasma fractalkine was greater 
among participants with ADHD/ASD comorbidity (U=2.39, p=0.016). Psychosis severity in 
these patients is often over-estimated due to the presence of ADHD/ASD. Taking the reduced 
duration of psychiatric syndrome and presence of ADHD/ASD as indicators of less severe 
psychotic disorders we reasoned that the fractalkine response to exercise intervention was a 
result of less severe profile in the patients at baseline. 
 
4.3.4 Those with high fractalkine level before and/or after exercise had an 
altered immune activity profile at baseline 
IL-12, Eotaxin-1, VEGF, IL-17A, TRAIL and IFN-γ had differing baseline levels in patients 
when they were grouped as fractalkine response groups versus healthy controls, with the 
exception of the “stably low” group of patients. The “stably low” group of patients had a similar 
profile to the healthy controls of the study, while the other groups, responders, non-responders 
and reverse responders had similar immune activity profiles. IL-12 levels were elevated in 
patients (p<0.01) compared to controls while stably low sub-group of patients had lower levels 
of IL-12 than the responders (p<0.01) and non-responders (p<0.01). Patients as a whole had 
lower levels of Eotaxin-1 compared to healthy controls and in addition responders had lower 
levels of Eotaxin-1 compared to the stably low patient group.  VEGF levels were higher in 
healthy controls compared to patients (p<0.01). VEGF levels were higher in responders 
(p<0.01) and reverse responders (p=0.03) compared to non-responders. IL-17A levels were 
higher in patients as a whole compared to healthy controls (p<0.01), and the stably low group 
had lower levels of IL-17A compared to the responders (p<0.01), non-responders (p<0.01) and 
reverse responders (p=0.01). Interestingly, a dysregulation of all of the above-mentioned 
cytokines have been reported in patient cohorts of psychotic disorders such as schizophrenia 
27-32. Comparable to our observation of reduced levels of IFNγ in the plasma, the authors 
Freudenreich et. al, have observed that cellular immunity is impaired in patients of 
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schizophrenia compared to healthy controls when PBMCs were analyzed for mRNA level 
expression of IFNγ141. Baseline levels of IL-12, Eotaxin-1, VEGF, IL-17A, IFN-γ and TRAIL 
showed differences between the fractalkine response groups, such that the stably low group 
had a pattern at baseline resembling healthy controls, while the other groups, each with high 
fractalkine level at least once, were at baseline indistinguishable from each other displaying 
elevated IL-12 and IL-17A and reduced Eotaxin-1, VEGF, TRAIL and IFN-γ levels, a cytokine 
profile indicating a dysregulation of the baseline immune activity in these 37 FEP patients 
(76% of the studied cohort). Similar to IL-12 and IL-17A, TRAIL levels were higher in healthy 
controls compared to patients as a whole (p<0.01). The stably low group of patients were 
comparable to healthy controls and had higher TRAIL levels than the group of responders 
(p=0.028). TRAIL has been linked with the ongoing pathology of schizophrenia and 
psychosis142. TRAIL, a relatively recently described protein ligand mediating apoptosis and 
member of the Tumor Necrosis Factor (TNF) family143 of proteins, has little relevant literature 
in the field of schizophrenia and psychosis. Nonetheless our findings resonate with the growing 
understanding that TRAIL together with TNF-related weak inducer of apoptosis (TWEAK), 
another recently described member of the TNF family, have salient roles in the progression of 
neuro-inflammation in patients of schizophrenia and psychosis142. Interestingly we see reduced 
levels of cytokines i.e. IFNγ and TRAIL, in the same patients who fall in the category of high 
fractalkine at one or both of the timepoints measured, compared to healthy controls. This could 
be a result of the feedback which is necessitated by high levels of fractalkine in plasma, as IFNγ 
and TNFα are part of the battery of cytokines which promotes the release of membrane bound 
fractalkine into circulation. Taken together this puts forth the case for further research into 
fractalkine as a marker for ongoing inflammation in patients with psychosis. 
 
4.3.5 The fractalkine response groups were distinct in Gro-α and IL-18 
changes. 
The three fractalkine response groups with apparently similarly altered baseline immune 
activity could be differentiated by studying the change in Gro-α and IL-18 levels over the 
exercise intervention. Gro-α levels increased over exercise intervention in the non-responders 
and reverse responders compared to responders and the stably low group (p<0.01). There was 
a trend for IL-18 levels to increase in the reverse responders group compared to the responders. 
Thus, Gro-α and IL-18 level change over intervention correlated highly to fractalkine level 
change over intervention and thereby demarcated the groups responders, non-responders and 
reverse responders from each other, supporting that the dysregulated immune activity in these 
groups could be modulated by physical exercise. Interestingly, and in parallel to our finding 
that Gro-α levels are distinctly different between the response groups it has been reported that 
Gro-α is dysregulated in FEP patients who suffered structural changes in brain such as white 
matter pathology32. Comparable to our finding that IL-18 levels are highest in the ‘reverse 
responder’ group compared to the ‘stably low’ and healthy controls and other patients, it has 
been shown that IL-18 is increased in the plasma of FEP compared to healthy controls and is 
correlated with cognitive dysfunction144. 
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5 SUMMARY AND CONCLUDING REMARKS 
Here, the constituent papers are summarized with some concluding and general remarks. The 
constituent papers belong to larger projects which are ongoing and in search of better diagnostic 
tools and therapeutic options for psychotic disorders. Investigations in independent cohorts and 
replications are warranted and humbly requested. 
 In Paper I we investigated the amount of  DNA in mitochondria which is a proxy for 
mitochondrial biogenesis and functionality, for association with psychosis severity and 
treatment of psychotic disorders. We confirmed earlier reports that mtDNA copy 
number was associated with age. We investigated mtDNA in peripheral tissue 
(leukocytes) and CNS tissue (cultured human neurons) and saw that certain types of 
anti-psychotic treatment can be deleterious to mtDNA in both tissues. Secondary to 
treatment effects we saw that mtDNA copy number was associated with psychosis 
severity as measured by CGI-S index. 
 As indicated in Paper II and III, patients with psychotic disorder such as, 
schizophrenia, are pre-disposed to metabolic comorbidities and thus shorter life span. 
In such patient cohorts, it could be useful to determine the accelerated ageing through 
analysis of the blood. We found elevated levels of GDF-15, an analyte previously 
shown to be associated with increased age, CVD and diabetes. Our findings point us to 
plasma GDF-15 as a potential tool in diagnosing accelerated ageing in patients of 
psychotic disorder. 
 As a follow up to Paper II, in Paper III we asked the question if increase in plasma 
GDF-15 level was associated with latent CVD in a patient cohort of psychotic 
disorders. We found that the GDF-15 levels correlated with levels of two established 
analyte biomarkers of CVD but was not associated with an indicator of acute or chronic 
inflammation, CRP.  
 In Paper IV, we investigated exercise intervention in patients of FEP, as an adjunct 
therapy. Of the analytes we measured based on an inflammation related hypothesis 
fractalkine levels were attenuated through exercise intervention. Interestingly response 
to intervention as defined by changes in fractalkine levels helped us meaningfully group 
the patient cohort from an inflammation biology point of view. The sub-groups had 
differing clinical profiles at baseline where we saw that a group of patients had a similar 
inflammation profile to healthy controls.  
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6 FUTURE PERSPECTIVES 
This thesis is intended to summarize the knowledge we have gained from analyzing material 
obtained from patients with psychosis for the goal of improved diagnostic tools and therapeutic 
options available to said patients. With that goal in mind, I would like to extend a few 
perspectives for the future, on work that should be carried out to build on our findings for 
eventually clinical applications. 
1. Our findings in the plasma represent information mainly centered on the systemic 
circulation of patients. While it is a strength that our analysis and work were conducted 
wholly in human material, thus having relevance for improving our understanding of 
human biology, schizophrenia and other psychotic disorders are disorders primarily of 
the CNS. As the CNS is fed by CSF that we know is relatively isolated from the 
systemic circulation system by the blood brain barrier, the thesis would benefit from 
having information on the constituent molecules of the CSF, in particular those 
described in more detail in the thesis, GDF-15, mtDNA and fractalkine and how well 
CSF values correlate with those measures in plasma. The blood brain barrier has been 
shown to be compromised in at least some kinds of psychotic disorders145 which adds 
credence to the theory that alterations in the inflammatory profile of the systemic 
circulation may have an impact on the CSF16.  
 
2. In Paper II and Paper III we reported that GDF-15 levels are associated with age in 
psychosis patients, which has been reported previously in individuals without severe 
mental illness 123. This information could be potentially used in disease monitoring, 
especially relevant in patients with psychotic disorders as they are prone to accelerated 
ageing and shorter life span. However, in Paper II we noted that GDF-15 levels were 
inversely associated with psychosis severity, that is, with increasing psychosis severity 
the levels of GDF-15 receded. Without a longitudinal design, it is difficult to estimate 
the relevance of GDF-15 as an all-cause mortality marker or an indicator of biological 
ageing. Currently it is understood that GDF-15 is secreted in low concentrations by 
most tissues, with defined roles in biological processes such as inflammation and 
apoptosis146. Interestingly it is upregulated in tissue injury, CVD and carcinogenesis33. 
However since little is known about the kinetics of plasma GDF-15 in the various 
pathological contexts147, the role of GDF-15 as a biomarker in those scenarios cannot 
yet be evaluated. Therefore more research is required into the expression, clearance and 
changes in the kinetics of plasma GDF-15. 
 
3. In Paper III we attempted to cast further light on the findings of Paper II. The 
increased levels of GDF-15 in the plasma of our study cohort of patients with psychotic 
disorder may well be due to multiple causes, in line with the literature describing GDF-
15 as an all-cause mortality marker123. In this study we compared the levels of GDF-15 
to levels of hs-CRP, NT-ProBNP and hs-cTnT, in order to evaluate whether GDF-15 
levels reflect CVD pathology. Indeed we saw that there were correlations with the CVD 
biomarkers (NT-ProBNP, hs-cTnT), but not with a marker of acute or general 
inflammation, CRP148. We expect GDF-15 levels to be associated with other categories 
of biomarkers relevant to CVD, such as, coagulation, vascular function, oxidative 
stress, structural and functional markers relating to atherosclerosis. 
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4. In Paper I we investigated the amount of mtDNA in whole blood as a marker of ageing, 
psychosis severity and anti-psychotic treatment. We saw that mtDNA copy number was 
reduced by certain types of antipsychotic treatment, both in wole blood and human 
neurons. Independently of this mtDNA was also reduced with age, and increasing 
psychosis severity The above study would benefit from a detailed analysis of the 
kinetics of mitochondrial fusion and fission as it is known that mitochondria conduct 
the production of ATP in dynamic and complex intracellular networks149. The changes 
in mtDNA as mitochondrion shift from discrete organelles to vesicular networks and 
back, through a process of fission and fusion, is poorly understood, and needs to be 
investigated further in vitro  ¸with respiration and functionality measures of OXPHOS 
using Seahorse XF Cell Mito Stress Test or OxyGraph, in parallel to studies similar to 
ours, 106,114 which track quantitative changes in mtDNA in cohorts of psychiatric 
patients.  
 
 
5. In Paper IV we observed that fractalkine, a chemokine mediator of neuroinflammation 
and migration of cellular mediators of immunity is dysregulated in some groups of FEP 
patients. We noted that overall as a cohort, the patients had elevated levels of 
fractalkine, however one sub-group of patients who had lowered levels of fractalkine, 
had an inflammation profile which more closely resembled the healthy controls than 
other patients who had registered high levels of fractalkine at one of the time points 
measured. In future studies of psychotic cohorts, investigators may frame a study that 
is dedicated to exploring all aspects of fractalkine biology hitherto known. This may 
include selecting the cytokines which induce and inhibit ftractalkine expression and 
release. In addition this study can be reproduced in psychosis relevant models, in vitro 
and in vivo. 
 
6. The projects outlined in this thesis aimed to provide pre-clinical evidence and basic 
research to back the use of novel comparisons between healthy individuals and patients 
of psychotic disorders, as markers of health, pathogenic process or pharmacologic 
response to therapy. With the findings of this project we hope to bring our novel 
observations to the threshold of basic research and one step closer to being considered 
as exploratory biomarkers. For this to occur, independent confirmation of our findings 
and more mechanistic substantiation of observations to establish casuality will be 
necessary. Therefore a limitation of this thesis, is that none of our observations can be 
considered grounds for the use of observed differences between patient and healthy 
controls as biomarkers, and a future direction for developing the project would be to 
take the necessary measures as outlined by regional Food and Drug administration 
bodies150,151 
 
 
 
 
 
“Do the difficult things while they are easy and do the great things while they are small.” 
Confucius 
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